Mycoplasma ovipneumoniae p71 antibody and antigen (recombinant protein)

Diagnostic anti-Mycoplasma ovipneumoniae p71 antibodies pairs and antigen for animal health (animal Ovines/Sheep infectious disease pneumonia) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Target products collectionGo to Ruminants disease testing products collection >>


Product information

Catalog No. Description US $ Price (per mg)
GMP-VT-P088-Tg001-Ag01 Recombinant Mycoplasma ovipneumoniae p71 protein $3090.00
GMP-VT-P088-Tg001-Ab01 Anti-Mycoplasma ovipneumoniae p71 mouse monoclonal antibody (mAb) $3090.00
GMP-VT-P088-Tg001-Ab02 Anti-Mycoplasma ovipneumoniae p71 mouse monoclonal antibody (mAb) $3090.00
GMP-VT-P088-Tg001-Ab03 Anti-Mycoplasma ovipneumoniae p71 human monoclonal antibody (mAb) $3090.00
GMP-VT-P088-Tg001-Ab04 Anti-Mycoplasma ovipneumoniae p71 human monoclonal antibody (mAb) $3090.00

Size: 1mg | 10mg | 100mg



Product Description

Cat No. GMP-VT-P088-Tg001-Ag01
Product Name Recombinant Mycoplasma ovipneumoniae p71 protein
Pathogen Mycoplasma ovipneumoniae
Expression platform E.coli
Isotypes Recombinant Antigen
Bioactivity validation Anti-Mycoplasma ovipneumoniae p71 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Mycoplasma ovipneumoniae level test of animal Ovines/Sheep infectious disease with pneumonia.
Tag His
Product description Recombinant Mycoplasma ovipneumoniae p71 proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No. GMP-VT-P088-Tg001-Ab01,GMP-VT-P088-Tg001-Ab02
Pathogen Mycoplasma ovipneumoniae
Product Name Anti-Mycoplasma ovipneumoniae p71 mouse monoclonal antibody (mAb)
Expression platform CHO
Isotypes Mouse IgG
Bioactivity validation Recombinant Mycoplasma ovipneumoniae p71 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Mycoplasma ovipneumoniae antibodies in Mycoplasma ovipneumoniae level test of animal Ovines/Sheep infectious disease with pneumonia.
Product description Anti-Mycoplasma ovipneumoniae p71 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Mycoplasma ovipneumoniae antibodies.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No. GMP-VT-P088-Tg001-Ab03,GMP-VT-P088-Tg001-Ab04
Pathogen Mycoplasma ovipneumoniae
Product Name Anti-Mycoplasma ovipneumoniae p71 human monoclonal antibody (mAb)
Expression platform CHO
Isotypes Human lgG1
Bioactivity validation Recombinant Mycoplasma ovipneumoniae p71 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Mycoplasma ovipneumoniae antibodies in Mycoplasma ovipneumoniae level test of animal Ovines/Sheep infectious disease with pneumonia.
Product description Anti-Mycoplasma ovipneumoniae p71 mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Pathogen Information


    Names of the Pathogen and Description:

    Pathogen Name: Capripox virus

    Description: Capripox virus is a significant pathogen that affects domestic and wild ruminants, including goats, sheep, and cattle. This virus is a member of the Poxviridae family, characterized by its brick-shaped morphology and complex genetic structure.

    Pathogen Classification:

    Capripox virus is classified as a virus, specifically belonging to the Poxviridae family. It does not fall into the categories of prokaryotic or eukaryotic organisms but rather belongs to the group of large, complex DNA viruses.

    Pathogen Structure (Main Gene and Protein):

    The Capripox virus has a complex structure with various genes and proteins. Its main genes and proteins include:

    Genes: The Capripox virus genome encodes a range of genes, including those responsible for the formation of structural and non-structural proteins. These genes include envelope proteins, DNA polymerase, and proteins involved in viral replication and transcription.

    Proteins: The major proteins within Capripox virus include those forming the viral envelope, capsid proteins, and various enzymes essential for viral replication and transcription.

    Hosts Infected by the Pathogen and Diseases:

    Capripox virus primarily infects domestic and wild ruminants. The diseases associated with Capripox virus infections include:

    1. Lumpy Skin Disease (LSD): This disease predominantly affects cattle. It is characterized by fever, nodules, skin lesions, and in severe cases, can lead to significant economic losses due to reduced milk and meat production.

    2. Sheeppox: Sheep are susceptible to Sheeppox, which causes fever, skin lesions, and sometimes severe respiratory symptoms. This disease can result in reduced wool and meat production, impacting the livelihood of farmers.

    3. Goatpox: Goatpox is similar to Sheeppox and primarily affects goats. It manifests with fever, skin nodules, and respiratory issues, leading to decreased milk and meat production.

    Diagnostic Methods (Including Nucleic Acids) and Target Genes/Proteins:

    Diagnostic methods for Capripox virus infections often involve molecular techniques, with a focus on the detection of nucleic acids. These methods target specific genes and proteins associated with the virus:

    Polymerase Chain Reaction (PCR): PCR is a widely employed method for detecting Capripox virus. It amplifies specific viral DNA sequences, commonly targeting genes like the DNA polymerase gene.

    Real-time PCR (qPCR): Real-time PCR is a quantitative technique that enables the detection and quantification of the virus. It can target various genes associated with Capripox virus.

    Enzyme-Linked Immunosorbent Assay (ELISA): ELISA detects viral antigens or antibodies produced in response to the virus. It often targets viral proteins, such as envelope proteins or specific antigens unique to Capripox virus.

    Loop-Mediated Isothermal Amplification (LAMP): LAMP is an isothermal amplification technique suitable for the rapid detection of Capripox virus. It targets specific gene regions.

    Sequencing: Sequencing of the viral genome allows for comprehensive characterization and identification of Capripox virus. This involves analyzing the entire genetic structure, including all the genes and proteins.

    The specific genes and proteins targeted in these diagnostic methods may vary depending on the particular assay and its intended purpose. Generally, they focus on genes associated with viral replication, such as the DNA polymerase gene, structural proteins, and unique antigens specific to Capripox virus. These diagnostic methods play a vital role in disease surveillance and control in affected ruminant populations.

    Treatment and Prevention:

    There is no specific antiviral treatment for Capripox virus infections in animals. Management primarily involves supportive care, including controlling fever and treating secondary bacterial infections that may arise due to skin lesions. In severe cases, it may be necessary to quarantine infected animals to prevent the spread of the virus to other livestock.

    Prevention of Capripox virus infections predominantly relies on vaccination and the implementation of biosecurity measures:

    Vaccination: Vaccination with live attenuated or inactivated vaccines has been widely used in many regions to protect susceptible livestock populations, especially in areas where the disease is endemic. These vaccines help in reducing the severity of clinical signs and curbing the spread of the virus.

    Biosecurity Measures: Implementing robust biosecurity measures, such as isolating infected animals and maintaining good hygiene practices, is crucial to prevent the introduction and spread of the virus within livestock populations. These measures help in reducing the risk of transmission between farms.

    Impact on Agriculture and Economy:

    Capripox virus infections can have a significant impact on agriculture and the economy of affected regions. The diseases caused by this virus can lead to various negative consequences, including:

    Reduced Milk and Meat Production: Lumpy Skin Disease in cattle and similar diseases in sheep and goats can result in decreased milk and meat production. This directly affects the income and livelihoods of farmers.

    Animal Weight Gain: Infected animals often experience reduced weight gain, which can delay the time to market or slaughter, causing financial losses to livestock producers.

    Mortality: In severe cases, Capripox virus infections can lead to fatalities, further increasing economic losses.

    Trade Restrictions: International trade restrictions may be imposed on regions or countries affected by Capripox virus outbreaks to prevent the spread of the disease to non-infected areas. These restrictions can disrupt international livestock trade, leading to financial losses for the livestock sector and affecting the overall economy.

    Given these potential economic consequences, it is essential for affected regions to implement effective control measures, including vaccination and biosecurity, to minimize the impact of Capripox virus on agriculture and the economy.

    Emerging Research and Developments:

    Research on Capripox virus continues to advance, with ongoing efforts to improve diagnostic methods, develop more effective vaccines, and understand the molecular biology of the virus. Some emerging areas of research and developments related to Capripox virus include:

    Vaccine Development: Scientists are working on the development of more efficient and safer vaccines for Capripox virus, including recombinant and subunit vaccines. These efforts aim to enhance the protection of livestock against Capripox virus infections, reducing the economic impact of the disease.

    Genomic Studies: Genomic sequencing and analysis of Capripox virus strains from different regions are helping researchers understand the genetic diversity of the virus. This knowledge can inform the development of more effective diagnostic tests and vaccines tailored to specific strains.

    Molecular Characterization: Ongoing research is focused on a detailed molecular characterization of the virus, including the identification of specific genes and proteins responsible for various aspects of viral replication and pathogenicity.

    Epidemiology and Surveillance: Scientists are continually improving epidemiological studies and surveillance techniques to track the spread of Capripox virus and identify risk factors for outbreaks.

    International Collaboration: Collaboration between countries and organizations is crucial for sharing information, resources, and best practices for the control and prevention of Capripox virus. International cooperation can help manage the global impact of the disease.

    In conclusion, Capripox virus is a significant pathogen affecting ruminants with a substantial economic impact on agriculture and trade. Ongoing research and developments are essential for controlling the disease and minimizing its



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.